● Recruiting

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Condition: HER2 Mutation-Related Tumors · HER2 · HER2-positive Breast Cancer · Sponsor: Iambic Therapeutics, Inc

PhasePhase 1

Planned participants383

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

This description comes directly from the study's public registry record.

Talk to the study team

Iambic Therapeutics, Inc., Senior Medical Director · 619-330-5499 · ClinicalTrials@Iambic.ai

Always discuss trial participation with your own doctor first.

Locations (53)

UCSD Moores Cancer Center	La Jolla, California, United States	Recruiting
USC Norris Comprehensive Cancer Center	Los Angeles, California, United States	Recruiting
University of Colorado Cancer Center	Aurora, Colorado, United States	Recruiting
University of Miami	Miami, Florida, United States	Recruiting
Comprehensive Hematology Oncology	St. Petersburg, Florida, United States	Recruiting
University of Chicago	Chicago, Illinois, United States	Recruiting
Massachusetts General Hospital	Boston, Massachusetts, United States	Recruiting
Dana Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting
University of Michigan	Ann Arbor, Michigan, United States	Recruiting
Henry Ford Cancer Institute	Detroit, Michigan, United States	Recruiting
START - Midwest Cancer Research Center	Grand Rapids, Michigan, United States	Recruiting
Saint Luke's Cancer Institute	Kansas City, Missouri, United States	Recruiting

+ 41 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06253871